Skoner David P, Gentile Deborah A, Doyle William J
Division of Allergy, Asthma, and Immunology, Department of Pediatrics, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA.
Ann Allergy Asthma Immunol. 2008 Oct;101(4):431-6. doi: 10.1016/S1081-1206(10)60322-5.
Guidelines recommend treatment with intranasal corticosteroids for patients with allergic rhinitis (AR), but concerns remain about possible adverse effects.
To present the 1- and 2-year growth results for children with AR treated with triamcinolone acetonide aqueous nasal spray.
Thirty-nine children (aged 6.1-14.3 years at study entry) were treated with triamcinolone acetonide aqueous for 1 year, and a subset of 30 children completed a second year of treatment. The dose was physician titered to achieve control over AR symptoms. For each child, statural heights at baseline and at the 1- and 2-year (where available) visits, together with growth rates, were measured and were compared with predicted values.
There were no significant differences between measured and predicted heights at the 1- and 2-year visits. The mean (SD) measured--predicted difference was 0.3 (2.2) cm (95% confidence interval, -0.4 to 1.0 cm) at the 1-year visit and 0.5 (3.0) cm (95% confidence interval, -0.6 to 1.6 cm) at the 2-year visit. Mean differences in measured and predicted growth rates were nonsignificant at the 1- and 2-year visits.
Triamcinolone acetonide aqueous titered to control AR symptoms and given for 1 or 2 years had no significant effect on statural growth in children with AR.
